Global Pharmaceutical CDMO Market Growth (Status and Outlook) 2023-2029

Global Pharmaceutical CDMO Market Growth (Status and Outlook) 2023-2029

The global Pharmaceutical CDMO market size is projected to grow from US$ 125480 million in 2022 to US$ 214600 million in 2029; it is expected to grow at a CAGR of 8.0% from 2023 to 2029.

The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider. The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider. In terms of its service type, the growth rate of FDF CDMO is relatively fast. At present, the market share of API CDMO is the highest, more than 40%, followed by FDF CDMO, packaging CDMO and clinical CDMO. In terms of its application, pharmaceutical company are the largest application field, with a market share of more than 60%, followed by biotechnology company.

A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.

Contract Pharmaceutical Manufacturing is part of CDMO, refers to accept commissioned from pharmaceutical companies, provide the service about API production, FDF production, packaging.

Pharmaceutical companies are likely to outsource a wide range of manufacturing related activities including – primary and secondary packaging, formulation, active ingredient manufacturing, labeling, clinical supplies, sterilization, manufacturing of chemical intermediates, etc. CDMOs support pharmaceutical companies at all stages of the process of making medicines: by providing services in the research and development stages, by offering support in manufacturing, and by providing formulating and finishing processes.

LPI (LP Information)' newest research report, the “Pharmaceutical CDMO Industry Forecast” looks at past sales and reviews total world Pharmaceutical CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Pharmaceutical CDMO sales for 2023 through 2029. With Pharmaceutical CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pharmaceutical CDMO industry.

This Insight Report provides a comprehensive analysis of the global Pharmaceutical CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pharmaceutical CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pharmaceutical CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pharmaceutical CDMO and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pharmaceutical CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of Pharmaceutical CDMO market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO

Segmentation by application
Pharmaceutical Company
Biotechnology Company
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL

Please note: The report will take approximately 2 business days to prepare and deliver.